Your shopping cart is currently empty

(+)-Fluprostenol (AL-5848), an analogue of prostaglandin F2 alpha, is a prostaglandin F2α receptor PTGFR agonist and decreases the expression of Oviductal glycoprotein 1 (OVGP1).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $77 | - | In Stock | |
| 5 mg | $189 | In Stock | In Stock | |
| 10 mg | $313 | - | In Stock | |
| 25 mg | $578 | - | In Stock | |
| 50 mg | $833 | - | In Stock | |
| 100 mg | $1,150 | - | In Stock | |
| 200 mg | $1,530 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $196 | - | In Stock |
| Description | (+)-Fluprostenol (AL-5848), an analogue of prostaglandin F2 alpha, is a prostaglandin F2α receptor PTGFR agonist and decreases the expression of Oviductal glycoprotein 1 (OVGP1). |
| In vivo | (+)-Fluprostenol(s.c. to rats on day 18 of pregnancy) increased cervical creep, or softness, by the following day. Doses of (+)-Fluprostenol 100-fold larger were necessary to increase uterine contractions. (+)-Fluprostenol produced falls in serum progesterone concentrations, increases in 20 alpha-dihydroprogesterone concentrations, no changes in oestradiol or relaxin concentrations and a reduction in the ovarian human chorionic gonadotrophin binding capacity in vitro. (+)-Fluprostenol was less potent in inducing cervical softness when administered per vaginam, and a dose which produced softening in pregnant rats was ineffective in ovariectomized steroid-maintained pregnant or pro-oestrous rats[3]. |
| Synonyms | Travoprost acid, Fluprostenol, (+)-, AL-5848 |
| Molecular Weight | 458.47 |
| Formula | C23H29F3O6 |
| Cas No. | 54276-17-4 |
| Smiles | O[C@@H](COc1cccc(c1)C(F)(F)F)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O |
| Relative Density. | 1.335 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 325 mg/mL (708.88 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8 mg/mL (17.45 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.